Wason JMS

Latest

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method
A review of Bayesian perspectives on sample size derivation for confirmatory trials
Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold
Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate
Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial
Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores
Graphical approaches for the control of generalised error rates
Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy
Two-stage sparse regression screening to detect biomarker-treatment interactions in randomized clinical trials
Simple MRI score aids prediction of dementia in cerebral small vessel disease
A web application for the design of multi-arm clinical trials
Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints
Two-stage adaptive designs for three-treatment bioequivalence studies
Bayesian design and analysis of external pilot trials for complex interventions
Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables
Admissible multiarm stepped‐wedge cluster randomized trial designs
A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints
Employing latent variable models to improve efficiency in composite endpoint analysis
Familywise error control in multi-armed response-adaptive trials
When to keep it simple - Adaptive designs are not always useful
Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: A case study
Group sequential crossover trial designs with strong control of the familywise error rate
Blinded and unblinded sample size reestimation in crossover trials balanced for period
Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials
Group sequential clinical trial designs for normally distributed outcome variables
Improving the analysis of composite endpoints in rare disease trials
An optimised multi-arm multi-stage clinical trial design for unknown variance
Adaptive designs in clinical trials: Why use them, and how to run and report them
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
Group sequential designs for stepped-wedge cluster randomised trials
Stepped wedge cluster randomized controlled trial designs: A review of reporting quality and design features
Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: An application of the augmented binary method
Use of an embedded, micro-randomised trial to investigate non-compliance in telehealth interventions
OptGS: An R package for finding near-optimal group-sequential designs
A Bayesian adaptive design for biomarker trials with linked treatments
Two-stage phase II oncology designs using short-term endpoints for early stopping
A review of statistical designs for improving the efficiency of phase II studies in oncology
The power of phase II end-points for different possible mechanisms of action of an experimental treatment
Design of telehealth trials – Introducing adaptive approaches
Recent Developments in Group-Sequential Designs
Correcting for multiple-testing in multi-arm trials: Is it necessary and is it done?
A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials
Reducing the average number of patients needed in a phase II trial through novel design
Using continuous data on tumour measurements to improve inference in phase II cancer studies
Planning multi-arm screening studies within the context of a drug development program.
Minimizing the maximum expected sample size in two-stage phase II clinical trials with continuous outcomes
A General Framework for Two-Stage Analysis of Genome-wide Association Studies and Its Application to Case-Control Studies
Optimal multistage designs for randomised clinical trials with continuous outcomes
Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis
Optimal design of multi-arm multi-stage trials
The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected
Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points
Comparison of multimarker logistic regression models, with application to a genomewide scan of schizophrenia